New drug discovery alliance launches
pharmafile | January 23, 2013 | News story | Research and Development, Sales and Marketing | CDRD, LDC, translational research
Six of the world’s top health science centres have banded together in an attempt to speed up the rate at which academic research is turned into new medicines.
The Global Alliance of Leading Drug Discovery and Development Centres will collaborate on drug development projects and contains two UK bodies: Medical Research Council Technology and Cancer Research Technology.
The other four are: Canada’s Centre for Drug Research and Development (CDRD), Germany’s Lead Discovery Center (LDC), the US’s Scripps Research Institute and Belgium’s Centre for Drug Design and Discovery (CD3).
These centres will cooperate with one another, developing standards and performance measures, while sharing best practice, expertise and resources.
“We see a multitude of translational research initiatives around the world, but until now, these have for the most part, worked in isolation of one another,” explained CDRD president Karimah Es Sabar.
“This alliance will be a powerful vehicle in bringing such organisations together, leveraging one another’s strengths, and ultimately making for a much more effective global translational research environment,” he added.
Taken together, the half dozen organisations represent nearly 400 drug developers collaborating with tens of thousands of academic scientists around the globe on 165 projects.
Adam Hill
Related Content

Roche unveils New York research base
Roche is to locate a new translational clinical research centre in central New York, as …
Roche unveils Zurich translational partnership
Roche has unveiled a new research collaboration with academic researchers and leading clinical centres in …

Roche launches R&D Institute in France
Roche has launched a new R&D Institute in France, furthering its links with academic centres …






